{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:47:15Z","timestamp":1755798435818,"version":"3.44.0"},"reference-count":246,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI155653, T32GM145304"],"award-info":[{"award-number":["1R01AI155653, T32GM145304"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The durability of vaccine-induced protection is a critical parameter in assessing the overall quality and long-term effectiveness of a vaccine. While the lifelong immunity conferred by certain vaccines is well recognized, the molecular components that underpin such long-lasting protection remain poorly understood. This knowledge gap is further complicated by the frequent inclusion of adjuvant formulations in licensed vaccines, the mechanisms of which are often multifaceted and not fully elucidated. In this review, drawing upon the portfolio of FDA-approved antiviral vaccines and incorporating insights from our own published studies in rodents, we propose that a virus-like structure - devoid of any engineered adjuvants - is all that is needed for a long-lasting IgG response in both mice and humans. This structure comprises two essential features: (1) the oriented display of viral surface protein antigens on a virus-sized scaffold, and (2) internal nucleic acids with native phosphodiester backbones. In fact, several inactivated virus vaccines that conform to this architecture have demonstrated effective and durable protection in human populations without the need for engineered adjuvants. Clarifying these structural and molecular determinants of viral immunogenicity may reduce the empirical nature of vaccine development, enable the rational design of next-generation self-adjuvanting antiviral vaccines, and inspire novel applications in noncommunicable diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1639371","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:19:46Z","timestamp":1755580786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular ingredients of an immunogen for long-lasting IgG"],"prefix":"10.3389","volume":"16","author":[{"given":"Sneh Lata","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Kay-Tsumagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev.med.56.082103.104549","article-title":"Effective cancer therapy through immunomodulation","volume":"57","author":"Waldmann","year":"2006","journal-title":"Annu Rev Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1517\/14728214.13.2.295","article-title":"Cancer vaccines: on the threshold of success","volume":"13","author":"Emens","year":"2008","journal-title":"Expert Opin Emerg Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1815","article-title":"Vaccines for tumour prevention","volume":"6","author":"Lollini","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e41756","DOI":"10.1371\/journal.pone.0041756","article-title":"Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes","volume":"7","author":"Faustman","year":"2012","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.227","article-title":"Development of an Interleukin-1beta vaccine in patients with type 2 diabetes","volume":"24","author":"Cavelti-Weder","year":"2016","journal-title":"Mol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4161\/hv.27520","article-title":"Hypertension Vaccine may be a boon to millions in developing world","volume":"10","author":"Bairwa","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer\u2019s disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0983","article-title":"Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with down syndrome: A phase 1b randomized clinical trial","volume":"79","author":"Rafii","year":"2022","journal-title":"JAMA Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.02.001","article-title":"Active immunotherapy for chronic diseases","volume":"31","author":"Bachmann","year":"2013","journal-title":"Vaccine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1086\/374419","article-title":"Vaccines, vaccination, and vaccinology","volume":"187","author":"Plotkin","year":"2003","journal-title":"J Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01359-z","article-title":"The persistence of memory: defining, engineering, and measuring vaccine durability","volume":"23","author":"Palin","year":"2022","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"21232","DOI":"10.1038\/s41598-022-25134-0","article-title":"Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex","volume":"12","author":"Korosec","year":"2022","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03278-y","article-title":"SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination","volume":"31","author":"Nguyen","year":"2025","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00956","article-title":"Role of multivalency and antigenic threshold in generating protective antibody responses","volume":"10","author":"Slifka","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.8248784","article-title":"The influence of antigen organization on B cell responsiveness","volume":"262","author":"Bachmann","year":"1993","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5246.173","article-title":"Immunology taught by viruses","volume":"271","author":"Zinkernagel","year":"1996","journal-title":"Science"},{"key":"B19","article-title":"New smallpox vaccines for an ancient scourge","volume":"111","author":"Frey","year":"2014","journal-title":"Mo Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/142.4.636","article-title":"A reality in our time\u2013certification of the global eradication of smallpox","volume":"142","author":"Wehrle","year":"1980","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting edge: long-term B cell memory in humans after smallpox vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J Immunol"},{"key":"B23","first-page":"1","article-title":"Second report","volume":"493","year":"1972","journal-title":"World Health Organ Tech Rep Ser"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00556-9","article-title":"Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis","volume":"12","author":"Schnyder","year":"2024","journal-title":"Lancet Glob Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz374","article-title":"Persistence of neutralizing antibody responses among yellow fever virus 17D vaccinees living in a nonendemic setting","volume":"221","author":"Kareko","year":"2020","journal-title":"J Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30323-8","article-title":"Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study","volume":"19","author":"Domingo","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02192","article-title":"Short-lived immunity after 17DD yellow fever single dose indicates that booster vaccination may be required to guarantee protective immunity in children","volume":"10","author":"Campi-Azevedo","year":"2019","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921388117","article-title":"Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine","volume":"117","author":"Wec","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"B31","first-page":"1","article-title":"and Prevention, Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI101633","article-title":"Protective effect of vaccination against induced influenza A","volume":"24","author":"Francis","year":"1945","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI101634","article-title":"Protective effect of vaccination against induced influenza B","volume":"24","author":"Salk","year":"1945","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1953.02940140013005","article-title":"Use of adjuvants in studies on influenza immunization. III. Degree of persistence of antibody in human subjects two years after vaccination","volume":"151","author":"Salk","year":"1953","journal-title":"J Am Med Assoc"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/136.Supplement_3.S450","article-title":"Clinical trials of monovalent influenza A\/New Jersey\/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence","author":"Cate","year":"1977","journal-title":"J Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2807\/ese.18.05.20389-en","article-title":"Vaccine effectiveness of 2011\/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection","volume":"18","author":"Pebody","year":"2013","journal-title":"Euro Surveill"},{"key":"B37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/1471-2334-13-441","article-title":"Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011\u20132012 season in Spain, among population targeted for vaccination","volume":"13","author":"Jimenez-Jorge","year":"2013","journal-title":"BMC Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix632","article-title":"Duration of influenza vaccine effectiveness: A systematic review, meta-analysis, and meta-regression of test-negative design case-control studies","volume":"217","author":"Young","year":"2018","journal-title":"J Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.013","article-title":"Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis","volume":"35","author":"Young","year":"2017","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy770","article-title":"Intraseason waning of influenza vaccine effectiveness","volume":"68","author":"Ray","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00141-X","article-title":"The role of live influenza vaccines in children","author":"Gruber","year":"2002","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.2.137","article-title":"Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial","volume":"282","author":"Nichol","year":"1999","journal-title":"JAMA"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805143382002","article-title":"The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children","volume":"338","author":"Belshe","year":"1998","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis641","article-title":"Localized mucosal response to intranasal live attenuated influenza vaccine in adults","volume":"207","author":"Barria","year":"2013","journal-title":"J Infect Dis"},{"key":"B45","first-page":"25","article-title":"An overview of serum antibody responses to influenza virus antigens","volume":"115","author":"Couch","year":"2003","journal-title":"Dev Biol (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"key":"B47","article-title":"Paralytic poliomyelitis-United States, 1980-1994","volume":"277","year":"1997","journal-title":"JAMA"},{"key":"B48","first-page":"1","article-title":"Advisory committee immunization poliomyelitis prev United States. Updated recommendations Advisory Committee Immunization Practices (ACIP)","volume":"49","author":"Prevots","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1955.02960140001001","article-title":"Considerations in the preparation and use of poliomyelitis virus vaccine","volume":"158","author":"Salk","year":"1955","journal-title":"J Am Med Assoc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(60)91791-8","article-title":"Persistence of immunity after administration of formalin-treated poliovirus vaccine","volume":"2","author":"Salk","year":"1960","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80228-8","article-title":"Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants","volume":"120","author":"Adenyi-Jones","year":"1992","journal-title":"J Pediatr"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.provac.2011.10.008","article-title":"Human vaccines and their importance to public health","volume":"5","author":"Schuchat","year":"2011","journal-title":"Proc Vaccinol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.18.2155","article-title":"Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States","volume":"298","author":"Roush","year":"2007","journal-title":"JAMA"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-165-40979","article-title":"Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27\/3 rubella virus","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03720210023022","article-title":"Rubella antibody persistence after immunization. Sixteen-year follow-up in the Hawaiian Islands","volume":"259","author":"Chu","year":"1988","journal-title":"JAMA"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1976.03260460021015","article-title":"Rubella immunization. Persistence of antibody four years after a large-scale field trial","volume":"235","author":"Herrmann","year":"1976","journal-title":"JAMA"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03320270031018","article-title":"Rubella antibody persistence after immunization","volume":"247","author":"Herrmann","year":"1982","journal-title":"JAMA"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1086\/528993","article-title":"Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up","volume":"197","author":"Davidkin","year":"2008","journal-title":"J Infect Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1086\/590115","article-title":"Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak","volume":"198","author":"Rubin","year":"2008","journal-title":"J Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1086\/596207","article-title":"Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine","volume":"2009","author":"LeBaron","year":"199","journal-title":"J Infect Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis568","article-title":"Waning antibody levels and avidity: implications for MMR vaccine-induced protection","volume":"206","author":"Kontio","year":"2012","journal-title":"J Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.057","article-title":"Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal","volume":"33","author":"Goncalves","year":"2015","journal-title":"Vaccine"},{"key":"B63","first-page":"1","article-title":"Advisory Committee on Immunization Practices Centers for Disease, and Prevention, Human rabies prevention\u2013United States, 2008: recommendations of the Advisory Committee on Immunization Practices","volume":"57","author":"Manning","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400070583","article-title":"Evaluation of a human diploid cell strain rabies vaccine: final report of a three year study of pre-exposure immunization","volume":"89","author":"Turner","year":"1982","journal-title":"J Hyg (Lond)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1086\/515267","article-title":"Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy","volume":"177","author":"Strady","year":"1998","journal-title":"J Infect Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J Infect Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114061","article-title":"The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions","volume":"121","author":"Heyward","year":"1985","journal-title":"Am J Epidemiol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/307178a0","article-title":"Human hepatitis B vaccine from recombinant yeast","volume":"307","author":"McAleer","year":"1984","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/infdis\/jiv748","article-title":"Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose","volume":"214","author":"Bruce","year":"2016","journal-title":"J Infect Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.11.037","article-title":"Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine","volume":"31","author":"Gilca","year":"2013","journal-title":"Vaccine"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2003.tb02477.x","article-title":"Decreased immune response to hepatitis B eight years after routine vaccination in Israel","volume":"92","author":"Gold","year":"2003","journal-title":"Acta Paediatr"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000176617.63457.9f","article-title":"Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth","volume":"24","author":"Dentinger","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67568-X","article-title":"Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study","volume":"366","author":"Zanetti","year":"2005","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.05.021","article-title":"Minimization of hepatitis B infection by a 25-year universal vaccination program","volume":"57","author":"Ni","year":"2012","journal-title":"J Hepatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"896","DOI":"10.4161\/hv.19989","article-title":"Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers","volume":"8","author":"Poovorawan","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058029","article-title":"Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose","volume":"8","author":"Mendy","year":"2013","journal-title":"PLoS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6715a5","article-title":"Recommendations of the advisory committee on immunization practices for use of a hepatitis B vaccine with a novel adjuvant","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.04.028","article-title":"Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease","volume":"41","author":"Girndt","year":"2023","journal-title":"Vaccine"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198809083191004","article-title":"Protection against Japanese encephalitis by inactivated vaccines","volume":"319","author":"Hoke","year":"1988","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91036-A","article-title":"Further experience with Japanese encephalitis vaccine","volume":"335","author":"Sanchez","year":"1990","journal-title":"Lancet"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.12.080","article-title":"Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity","volume":"28","author":"Reisler","year":"2010","journal-title":"Vaccine"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00041-4","article-title":"Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains","volume":"18","author":"Kurane","year":"2000","journal-title":"Vaccine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","article-title":"Japanese encephalitis vaccine: recommendations of the advisory committee on immunization practices","volume":"68","author":"Hills","year":"2019","journal-title":"MMWR Recomm Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.037","article-title":"Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis","volume":"33","author":"Paulke-Korinek","year":"2015","journal-title":"Vaccine"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.03.030","article-title":"Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO(R) in healthy adults: A five year follow-up study","volume":"37","author":"Taucher","year":"2019","journal-title":"Vaccine"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2028513","DOI":"10.1080\/21645515.2022.2028513","article-title":"Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children","volume":"18","author":"Hattasingh","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B88","doi-asserted-by":"publisher","first-page":"104476","DOI":"10.1016\/j.meegid.2020.104476","article-title":"Neutralizing antibody rather than cellular immune response is maintained for nearly 20 years among Japanese encephalitis SA14-14\u20132 vaccinees in an endemic setting","volume":"85","author":"Wang","year":"2020","journal-title":"Infect Genet Evol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.12.13057","article-title":"Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum Vaccin"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.09.018","article-title":"Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children","volume":"34","author":"Chokephaibulkit","year":"2016","journal-title":"Vaccine"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.Supplement_3.S310","article-title":"Varicella vaccine: the Japanese experience","volume":"174","author":"Asano","year":"1996","journal-title":"J Infect Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064040","article-title":"Loss of vaccine-induced immunity to varicella over time","volume":"356","author":"Chaves","year":"2007","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1086\/338959","article-title":"Persistence of immunity to live attenuated varicella vaccine in healthy adults","volume":"34","author":"Ampofo","year":"2002","journal-title":"Clin\u00a0Infect Dis"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6905a1","article-title":"Prevention of hepatitis A virus infection in the United States: recommendations of the advisory committee on immunization practices, 2020","volume":"69","author":"Nelson","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.12.054","article-title":"Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil","volume":"37","author":"Souto","year":"2019","journal-title":"Vaccine"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001322","article-title":"Single-dose universal hepatitis A immunization in one-year-old children in Argentina: high prevalence of protective antibodies up to 9 years after vaccination","volume":"35","author":"Uruena","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28375","article-title":"Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up","volume":"63","author":"Spradling","year":"2016","journal-title":"Hepatology"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4161\/hv.18617","article-title":"Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine","volume":"8","author":"Herck","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.088","article-title":"Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults","volume":"32","author":"Hens","year":"2014","journal-title":"Vaccine"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.008","article-title":"Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions","volume":"33","author":"Theeten","year":"2015","journal-title":"Vaccine"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B103","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.coi.2017.06.009","article-title":"No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines","volume":"47","author":"Mitchell","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.2.13948","article-title":"The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay","volume":"7","author":"Brown","year":"2011","journal-title":"Hum Vaccin"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1065363","article-title":"Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study","volume":"12","author":"Romanowski","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B108","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgae032","article-title":"HPV16\/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial","volume":"2024","author":"Porras","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"B110","first-page":"1","article-title":"Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"58","author":"Cortese","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"B111","article-title":"Reduction in rotavirus after vaccine introduction\u2013United States, 2000-2009","volume":"58","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ872","article-title":"Long-term consistency in rotavirus vaccine protection: RV5 and RV1 vaccine effectiveness in US children, 2012-2013","volume":"61","author":"Payne","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piw061","article-title":"Sustained high effectiveness of rotaTeq on hospitalizations attributable to rotavirus-associated gastroenteritis during 4 years in Finland","volume":"6","author":"Hemming-Harlo","year":"2017","journal-title":"J Pediatr Infect Dis Soc"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1017","article-title":"Effectiveness of pentavalent rotavirus vaccine against a diverse range of circulating strains in Nicaragua","volume":"62","author":"Patel","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix670","article-title":"Waxing understanding of waning immunity","volume":"217","author":"Lopman","year":"2018","journal-title":"J Infect Dis"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix668","article-title":"Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: A clinical trial in dhaka, Bangladesh (PROVIDE) and a simulation study","volume":"217","author":"Rogawski","year":"2018","journal-title":"J Infect Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged >\/=60 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: A cohort study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw854","article-title":"Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the medicare population ages 65 years and older","volume":"64","author":"Izurieta","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa300","article-title":"Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination","volume":"224","author":"Hastie","year":"2021","journal-title":"J Infect Dis"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-092818-015550","article-title":"Adenovirus entry: from infection to immunity","volume":"6","author":"Greber","year":"2019","journal-title":"Annu Rev Virol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6639a2","article-title":"Human adenovirus surveillance - United States, 2003-2016","volume":"66","author":"Binder","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.035","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits","volume":"31","author":"Kuschner","year":"2013","journal-title":"Vaccine"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.07.033","article-title":"Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits","volume":"34","author":"Choudhry","year":"2016","journal-title":"Vaccine"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030411","article-title":"Live oral adenovirus type 4 and type 7 vaccine induces durable antibody response","volume":"8","author":"Collins","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu507","article-title":"Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines","volume":"59","author":"Radin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7006a1","article-title":"Dengue vaccine: recommendations of the advisory committee on immunization practices, United States, 2021","volume":"70","author":"Paz-Bailey","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaq0215","article-title":"Advancing dengue vaccine development","volume":"358","author":"Feinberg","year":"2017","journal-title":"Science"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1811986","article-title":"Dengue serostatus and dengue vaccine safety and efficacy","volume":"379","author":"Posfay-Barbe","year":"2018","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMc1811986","article-title":"Dengue serostatus and dengue vaccine safety and efficacy","volume":"379","author":"Slifka","year":"2018","journal-title":"N Engl J Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3527(08)60268-7","article-title":"Antibody-dependent enhancement of viral infectivity","volume":"31","author":"Porterfield","year":"1986","journal-title":"Adv Virus Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai8128","article-title":"IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity","volume":"355","author":"Wang","year":"2017","journal-title":"Science"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.729210","article-title":"Quantitative correlation between infectivity and gp120 density on HIV-1 virions revealed by optical trapping virometry","volume":"291","author":"DeSantis","year":"2016","journal-title":"J Biol Chem"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01392-9","article-title":"Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection","volume":"27","author":"Salje","year":"2021","journal-title":"Nat Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1126012","article-title":"Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naive vaccinees","volume":"12","author":"Velumani","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B147","article-title":"Notes from the field: chikungunya virus spreads in the Americas - Caribbean and South America, 2013-2014","volume":"63","author":"Fischer","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2000.62.681","article-title":"Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218","volume":"62","author":"Edelman","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B152","doi-asserted-by":"publisher","first-page":"e1000908","DOI":"10.1371\/journal.ppat.1000908","article-title":"Few and far between: how HIV may be evading antibody avidity","volume":"6","author":"Klein","year":"2010","journal-title":"PLoS Pathog"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide-based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.099","article-title":"A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection","volume":"33","author":"Melgaco","year":"2015","journal-title":"Vaccine"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1541407","article-title":"Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine","volume":"17","author":"Korenkov","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.20.25328004","article-title":"Oral live attenuated polio vaccines induce enhanced T-cell responses with broad antigen recognition compared to inactivated polio vaccines","author":"Snyder","year":"2025","journal-title":"medRxiv"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7030110","article-title":"The cellular immune response to rabies vaccination: A systematic review","volume":"7","author":"Overduin","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02447-13","article-title":"A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251","volume":"88","author":"Rompay","year":"2014","journal-title":"J Virol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.01.011","article-title":"Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response","volume":"34","author":"Hou","year":"2011","journal-title":"Immunity"},{"key":"B160","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.immuni.2018.08.012","article-title":"B cells are the dominant antigen-presenting cells that activate naive CD4(+) T cells upon immunization with a virus-derived nanoparticle antigen","volume":"49","author":"Hong","year":"2018","journal-title":"Immunity"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01597-9","article-title":"Molecular basis for potent B cell responses to antigen displayed on particles of viral size","volume":"24","author":"Brooks","year":"2023","journal-title":"Nat Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/vaccines12040405","article-title":"Minimal determinants for lifelong antiviral antibody responses from a single exposure to virus-like immunogens at low doses","volume":"12","author":"Wholey","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.28.577643","article-title":"An integrated signaling threshold initiates IgG response towards virus-like immunogens","volume":"213","author":"Wholey","year":"2024","journal-title":"J Immunol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.07.020","article-title":"The density code for the development of a vaccine","volume":"105","author":"Cheng","year":"2016","journal-title":"J Pharm Sci"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.9b00825","article-title":"Synthetic liposomal mimics of biological viruses for the study of immune responses to infection and vaccination","volume":"31","author":"Wholey","year":"2020","journal-title":"Bioconjug Chem"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.1c00463","article-title":"Site-specific and stable conjugation of the SARS-coV-2 receptor-binding domain to liposomes in the absence of any other adjuvants elicits potent neutralizing antibodies in BALB\/c mice","volume":"32","author":"Wholey","year":"2021","journal-title":"Bioconjug Chem"},{"key":"B167","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41541-023-00621-1","article-title":"Impact of host genetic polymorphisms on response to inactivated influenza vaccine in children","volume":"8","author":"Tsang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.8b00033","article-title":"Quantitation and stability of protein conjugation on liposomes for controlled density of surface epitopes","volume":"29","author":"Chen","year":"2018","journal-title":"Bioconjug Chem"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.5816","article-title":"Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model","volume":"180","author":"Chackerian","year":"2008","journal-title":"J Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11849","article-title":"Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies","volume":"108","author":"Chackerian","year":"2001","journal-title":"J Clin Invest"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1126\/science.2994218","article-title":"Three-dimensional structure of poliovirus at 2.9 A resolution","volume":"229","author":"Hogle","year":"1985","journal-title":"Science"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"key":"B173","doi-asserted-by":"publisher","first-page":"17478","DOI":"10.1038\/s41598-020-74288-2","article-title":"Cell-free DNA in plasma as an essential immune system regulator","volume":"10","author":"Korabecna","year":"2020","journal-title":"Sci Rep"},{"key":"B174","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","article-title":"Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses","volume":"56","author":"Ols","year":"2023","journal-title":"Immunity"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.4878","article-title":"Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs","volume":"167","author":"Ballas","year":"2001","journal-title":"J Immunol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.791416","article-title":"Single stranded fully modified-phosphorothioate oligonucleotides can induce structured nuclear inclusions, alter nuclear protein localization and disturb the transcriptome in vitro","volume":"13","author":"Flynn","year":"2022","journal-title":"Front Genet"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2023.0056","article-title":"Sequence- and structure-dependent cytotoxicity of phosphorothioate and 2\u2019-O-methyl modified single-stranded oligonucleotides","volume":"34","author":"Croft","year":"2024","journal-title":"Nucleic Acid Ther"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.1860090210","article-title":"Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides","volume":"9","author":"Srinivasan","year":"1995","journal-title":"J Clin Lab Anal"},{"key":"B180","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B181","doi-asserted-by":"publisher","first-page":"eabo4184","DOI":"10.1126\/sciadv.abo4184","article-title":"Cryo-EM structures of human hepatitis B and woodchuck hepatitis virus small spherical subviral particles","volume":"8","author":"Liu","year":"2022","journal-title":"Sci Adv"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp1453","article-title":"Inherent symmetry and flexibility in hepatitis B virus subviral particles","volume":"385","author":"Wang","year":"2024","journal-title":"Science"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.05.005","article-title":"Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques","volume":"41","author":"Choi","year":"2023","journal-title":"Vaccine"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80449-9","article-title":"Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16","volume":"5","author":"Chen","year":"2000","journal-title":"Mol Cell"},{"key":"B185","doi-asserted-by":"publisher","first-page":"100030","DOI":"10.1016\/j.jvacx.2019.100030","article-title":"Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch in rhesus macaques: An exploratory, pre-clinical feasibility assessment","volume":"2","author":"Meyer","year":"2019","journal-title":"Vaccine X"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1328332","article-title":"Immunogenicity, safety and tolerability of intradermal influenza vaccines","volume":"14","author":"Hung","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/137.6.783","article-title":"Immunization with a human diploid cell strain of rabies virus vaccine: two-year results","volume":"3","author":"Nicholson","year":"1978","journal-title":"J Infect Dis"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00133-X","article-title":"Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial","volume":"16","author":"Beals","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.61.1.50-59.1987","article-title":"Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses","volume":"61","author":"Cohen","year":"1987","journal-title":"J Virol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.4.749","article-title":"Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures","volume":"153","author":"Binn","year":"1986","journal-title":"J Infect Dis"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(93)90204-B","article-title":"Preparation and immunogenicity of an inactivated hepatitis A vaccine","volume":"11","author":"Pellegrini","year":"1993","journal-title":"Vaccine"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00317-6","article-title":"Novel chikungunya vaccine shows promise for durable protection","volume":"22","author":"Stephenson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00435.020","article-title":"Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization","volume":"2","author":"Sun","year":"2013","journal-title":"Elife"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.cell.2019.04.006","article-title":"Cryo-EM structure of chikungunya virus in complex with the mxra8 receptor","volume":"177","author":"Basore","year":"2019","journal-title":"Cell"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01382-20","article-title":"Berberine chloride is an alphavirus inhibitor that targets nucleocapsid assembly","volume":"11","author":"Wan","year":"2020","journal-title":"mBio"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.5309-5319.1999","article-title":"In vitro assembly of alphavirus cores by using nucleocapsid protein expressed in Escherichia coli","volume":"73","author":"Tellinghuisen","year":"1999","journal-title":"J Virol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00619-06","article-title":"Alphavirus capsid protein helix I controls a checkpoint in nucleocapsid core assembly","volume":"80","author":"Hong","year":"2006","journal-title":"J Virol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350437","article-title":"B cell-intrinsic TLR7 signaling is required for neutralizing antibody responses to SARS-CoV-2 and pathogen-like COVID-19 vaccines","volume":"53","author":"Miquel","year":"2023","journal-title":"Eur J Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat Immunol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00577-0","article-title":"Regulation of the nucleic acid-sensing Toll-like receptors","volume":"22","author":"Lind","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1038\/nri1957","article-title":"Toll-like receptors in systemic autoimmune disease","volume":"6","author":"Marshak-Rothstein","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/10.6.2135","article-title":"Nucleotide sequence of human influenza A\/PR\/8\/34 segment 2","volume":"10","author":"Winter","year":"1982","journal-title":"Nucleic Acids Res"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.8.4887","article-title":"Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome","volume":"78","author":"Racaniello","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(88)90600-9","article-title":"Completion of the rabies virus genome sequence determination: highly conserved domains among the L (polymerase) proteins of unsegmented negative-strand RNA viruses","volume":"165","author":"Tordo","year":"1988","journal-title":"Virology"},{"key":"B206","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0042-6822(87)90144-9","article-title":"Complete nucleotide sequence of the Japanese encephalitis virus genome RNA","volume":"161","author":"Sumiyoshi","year":"1987","journal-title":"Virology"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac275","article-title":"An atlas of human viruses provides new insights into diversity and tissue tropism of human viruses","volume":"38","author":"Ye","year":"2022","journal-title":"Bioinformatics"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002218","article-title":"The fecal viral flora of wild rodents","volume":"7","author":"Phan","year":"2011","journal-title":"PLoS Pathog"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1612-6","article-title":"UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity","volume":"575","author":"Majer","year":"2019","journal-title":"Nature"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1611-7","article-title":"Release from UNC93B1 reinforces the compartmentalized activation of select TLRs","volume":"575","author":"Majer","year":"2019","journal-title":"Nature"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.07.013","article-title":"Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus","volume":"25","author":"Christensen","year":"2006","journal-title":"Immunity"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402425","article-title":"Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR\/TLR7-dependent responses","volume":"194","author":"Nundel","year":"2015","journal-title":"J Immunol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","article-title":"Toll-like receptor signalling in B cells during systemic lupus erythematosus","volume":"17","author":"Fillatreau","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093208","article-title":"Toll-like receptors 7 and 9 regulate the proliferation and differentiation of B cells in systemic lupus erythematosus","volume":"14","author":"Wen","year":"2023","journal-title":"Front Immunol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172219","article-title":"B cell-intrinsic TLR7 expression drives severe lupus in TLR9-deficient mice","volume":"8","author":"Cosgrove","year":"2023","journal-title":"JCI Insight"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01310-2","article-title":"Genetic dissection of TLR9 reveals complex regulatory and cryptic proinflammatory roles in mouse lupus","volume":"23","author":"Leibler","year":"2022","journal-title":"Nat Immunol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132328","article-title":"B cell-intrinsic TLR9 expression is protective in murine lupus","volume":"130","author":"Tilstra","year":"2020","journal-title":"J Clin Invest"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(02)02259-7","article-title":"Of mice and men: species variations of Toll-like receptor expression","volume":"23","author":"Rehli","year":"2002","journal-title":"Trends Immunol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1369\/0022155416656154","article-title":"The expression of toll-like receptors in normal human and murine gastrointestinal organs and the effect of microbiome and cancer","volume":"64","author":"Huhta","year":"2016","journal-title":"J Histochem Cytochem"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5321.2024","article-title":"The role of antibody concentration and avidity in antiviral protection","volume":"276","author":"Bachmann","year":"1997","journal-title":"Science"},{"key":"B221","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/v17040579","article-title":"Superior potency of synthetic virus-like structures in vaccine-induced antibody responses compared to Q\u03b2 Bacteriophage virus-like particles","volume":"17","author":"Meyer","year":"2025","journal-title":"Viruses"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B cell responses: cell interaction dynamics and decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"Cell"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0244-2","article-title":"B cell memory: building two walls of protection against pathogens","volume":"20","author":"Akkaya","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-00991-0","article-title":"New insights into the ontogeny, diversity, maturation and survival of long-lived plasma cells","volume":"24","author":"Fooksman","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00912.x","article-title":"Mechanisms that determine plasma cell lifespan and the duration of humoral immunity","volume":"236","author":"Amanna","year":"2010","journal-title":"Immunol Rev"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01345-5","article-title":"Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota","volume":"23","author":"Liu","year":"2022","journal-title":"Nat Immunol"},{"key":"B227","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.immuni.2023.04.015","article-title":"Intrinsically determined turnover underlies broad heterogeneity in plasma-cell lifespan","volume":"56","author":"Robinson","year":"2023","journal-title":"Immunity"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017004481","article-title":"Long-lived plasma cells in human bone marrow can be either CD19(+) or CD19()","volume":"1","author":"Brynjolfsson","year":"2017","journal-title":"Blood Adv"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801677","article-title":"Self-antigens displayed on liposomal nanoparticles above a threshold of epitope density elicit class-switched autoreactive antibodies independent of T cell help","volume":"204","author":"Chen","year":"2020","journal-title":"J Immunol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.immuni.2017.11.023","article-title":"Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens","volume":"48","author":"Abbott","year":"2018","journal-title":"Immunity"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/30.3.257","article-title":"Life-span and the inheritance of longevity of inbred mice","volume":"30","author":"Goodrick","year":"1975","journal-title":"J Gerontol"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-74-4-685","article-title":"Antigenic structure of poliovirus in inactivated vaccines","volume":"74","author":"Ferguson","year":"1993","journal-title":"J Gen Virol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.12.020","article-title":"Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine","volume":"37","author":"Quintel","year":"2019","journal-title":"Vaccine"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010695","article-title":"Development of a next-generation chikungunya virus vaccine based on the HydroVax platform","volume":"18","author":"Slifka","year":"2022","journal-title":"PLoS Pathog"},{"key":"B236","doi-asserted-by":"publisher","first-page":"101655","DOI":"10.1016\/j.xcrm.2024.101655","article-title":"Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model","volume":"5","author":"Amanna","year":"2024","journal-title":"Cell Rep Med"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00041-8","article-title":"In vivo absorption of aluminium-containing vaccine adjuvants using 26Al","volume":"15","author":"Flarend","year":"1997","journal-title":"Vaccine"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00170-6","article-title":"Elimination of aluminum adjuvants","volume":"20","author":"Hem","year":"2002","journal-title":"Vaccine"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.124","article-title":"Updated aluminum pharmacokinetics following infant exposures through diet and vaccination","volume":"29","author":"Mitkus","year":"2011","journal-title":"Vaccine"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"key":"B242","first-page":"493","article-title":"WHO position paper on hepatitis A vaccines - October 2022","volume":"97","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"B243","article-title":"Human papillomavirus vaccines: WHO position paper, December 2022","volume":"97","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"B244","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6908a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2020\u201321 influenza season","volume":"69","author":"Grohskopf","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"B245","article-title":"Seroprevalence of poliovirus antibodies among children in a Dominican community\u2013Puerto Rico, 2002","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B246","first-page":"1","article-title":"WHO expert committee on rabies","volume":"824","year":"1992","journal-title":"World Health Organ Tech Rep Ser"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639371\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:19:48Z","timestamp":1755580788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639371\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":246,"alternative-id":["10.3389\/fimmu.2025.1639371"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1639371","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"article-number":"1639371"}}